Clinical TrialMay 19, 2026, 09:02 AM
Lipocine LPCN 1154 Phase 3 Data Accepted for Oral Presentation at ASCP
AI Summary
Lipocine Inc. announced that its Phase 3 clinical data for LPCN 1154, an oral brexanolone for postpartum depression, has been accepted for both oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The oral presentation will detail results from the placebo-controlled trial, while a poster session will also feature the data. This highlights the progress of their proprietary technology platform for effective oral drug delivery.
Key Highlights
- Lipocine's LPCN 1154 Phase 3 data accepted for oral and poster presentation.
- Presentation to occur at the 2026 ASCP Annual Meeting in Miami, FL, May 26-29.
- Oral presentation titled "Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression".
- Dr. Benjamin Bruno, VP, Clinical Development, will present orally on May 26, 2026.
- A poster presentation is also scheduled for Wednesday, May 27, 2026.
- LPCN 1154 is an oral brexanolone being evaluated for postpartum depression (PPD).
Price Impact
More from LPCN